Theta tACS During Working Memory Training: A Pilot Study of the Effects on Negative Symptoms of Schizophrenia

September 20, 2020 updated by: Hsin-An Chang, MD, Tri-Service General Hospital

Online Left-hemispheric Frontoparietal Theta In-phase tACS During Working Memory Training in Schizophrenia Patients: A Pilot Randomized Double-blind, Sham-controlled Study of the Effects on Negative Symptoms

In this randomized double-blind trial, we investigated whether externally induced left-hemispheric frontoparietal theta synchronization by multi-electrode online theta (6Hz) transcranial alternating current stimulation (tACS) would enhance the influence of a working memory training on negative symptoms of schizophrenia.

Study Overview

Detailed Description

Negative symptoms have a negative impact on the prognosis of schizophrenia, but effective treatment for this symptom dimension is still under investigation. Identifying a treatment target that has a close link to negative symptoms or highly impacts negative symptoms may help to develop an effective therapy to counteract negative symptoms of schizophrenia. Recent theoretical and empirical work linking negative symptoms and cognitive impairment in schizophrenia has identified a potential treatment target: cognitive deficits. Evidence has indicated that cognitive remediation (CR) has a positive effect on improving negative symptoms of schizophrenia, in particular behavioural negative symptoms.

Although it is still debated which active components of CR contribute to the improvements in negative symptoms. The framework proposed by Gold and colleagues may be a candidate to explain how CR improves negative symptoms (i.e., possible through improving working memory). Anhedonia (i.e., the diminished ability to experience pleasure and reduced reactivity to pleasurable stimuli) represents a challenging negative symptom in schizophrenia.The impairment in hedonic processing has been associated with reduced motivation to engage in potentially rewarding events. Working memory (WM) plays an important role in the formation, maintenance, and retrieval of affective and value representations, all of which are essential for anticipatory pleasure. Individuals represent events and forecast pleasure by using WM in order to recruit motivational resources. It has been suggested that there is a hedonic detector system within the WM model and that WM serves as a potential underlying cognitive mechanism for anticipatory pleasure and goal-related behaviours. Problems in WM may reduce the ability to retrieve and manipulate information to motivate and guide future behaviour, thereby contributing to diminished motivation and the pleasure experience. It is known that the recruitment of the prefrontal-striatal system (including dorsolateral prefrontal cortex, cingulate cortex, insula, and ventral striatum) implicates in hedonic processing. It is also known that the same brain regions can be viewed as core brain regions of the WM network because they are activated during WM load. The overlap in activation of the prefrontal-striatal system during hedonic processing and WM provides robust evidence supporting the relationship between hedonic capacity and WM. Evidence indicated a correlation between the activity in WM brain networks and the improvement in negative symptoms following antipsychotic treatment, suggesting a mediating effect of WM on negative symptoms improvement in the context of a pharmacological intervention. More recently, studies indicated that 20 sessions of WM training (dual n-back task training) showed neural transfer effect to enhance hedonic processing in individuals with high social anhedonia and ameliorate hedonic dysfunction in schizophrenia patients with prominent negative symptoms.

In addition to WM training, non-invasive brain stimulation (NIBS) is also a non-pharmacological method to improve brain neural plasticity. For example, repetitive transcranial magnetic stimulation (rTMS) can change the activity of cortical nerve temporarily or continuously and enhance neural plasticity. However, the ability of rTMS alone to improve cognitive function in schizophrenia is frequently limited to some extent, necessitating a combination with WM training to boost cognitive functions.

Transcranial alternating current stimulation (tACS), a safe NIBS technique that applies low-intensity alternating current, is also a potential therapeutic option in treating the cognitive impairment in schizophrenia. The stimulation frequency of tACS is usually set to coincide with the targeted brain endogenous rhythms. It would synchronize the neural oscillations in the stimulated cortical regions to the applied stimulation frequency. Different tACS current intensity (0.5 to 4 mA), stimulation frequency (0.1 to 80 Hz), electrode montages, phase difference across the stimulation site, with/without DC offset, and the states (e.g., at rest or concurrently under the tasks) during stimulation contribute to its different effects. If both the target electrode and the reference electrode are in the same phase of the cycle of the current at any given time, the phase difference will be 0 degree (i.e., in-phase). The phase difference will be 180 degrees (i.e., anti-phase) if the electrodes are in the opposite phase. In-phase and anti-phase tACS over brain regions elicits synchronization and desynchronization of neuronal activity across the brain regions, respectively.

The state-dependent tACS effects indicate that the effects of tACS are enhanced when the state of the targeted brain regions is active. Specifically, synchronization of frontoparietal regions at theta frequencies dominates during an executive task. tACS at the frequency close to the theta oscillation activated by an executive task would elicit more resonance and may, in turn, help to enhance executive function. tACS applied when an individual is concurrently engaged in a specific cognitive task is defined as online tACS. In healthy subjects, online theta (6Hz) in-phase tACS facilitated frontoparietal phase coupling (synchronization) resulting in improved WM performance, whereas online theta (6Hz) anti-phase tACS disrupted theta phase-coupling (desynchonization) resulting in impaired WM performance.

The prolonged after-effects of tACS may be related to a phenomenon called spike-timing-dependent plasticity (STDP), a process that modifies the connection strengths based on the relative timing of the input and output spikes (or action potentials) of a neuron. STDP means that synapse will be strengthened if input action potentials occur immediately before the output action potentials, and synapse will be made weaker if an input action potentials occur immediately after an output action potentials. The STDP process is known to explain in part long-term depression (LTD) and long-term potentiation (LTP) of nervous systems. To sum up, tACS at a frequency close to that of resonance frequency during tACS may intensify the synapses across the stimulated regions through the mechanism of STDP. Repetitive (multiple-session) tACS during specific time intervals may consolidate the neuroplasticity effects, and may, in turn, elicit a long-lasting effect for further clinical application in treating neuropsychiatric disorders. In schizophrenia patients, a few case reports indicated 1-5 sessions of online theta in-phase tACS over left frontoparietal regions improved the performance of WM and several other cognitive domains.

So far, there is no relevant research report exploring whether and how the joint intervention (i.e., online theta (6Hz) in-phase tACS over the left frontoparietal regions plus WM training) will have a combined effect on improving the performance of WM and other cognitive domains in schizophrenic patients. Neither is any research investigating whether online theta (6Hz) in-phase tACS over the left frontoparietal regions can potentiate the effects of WM training on improving negative symptoms of schizophrenia. To sum up, we hypothesize that the combination training mode of active online theta tACS plus WM training would have a greater ability to reduce negative symptoms of schizophrenia compared to the training mode of sham online theta tACS plus WM training. The study aims to test the efficacy of "active online theta tACS plus WM" versus "sham online theta tACS plus WM training" in improving negative symptoms, WM performance, and other cognitive domains performance of schizophrenia using a double-blinded, randomized sham-controlled trial design. In order to evaluate the efficacy of the interventions, we will use behavioral outcomes (e.g., negative symptoms assessment and neurocognitive assessment) and neurophysiological outcomes (e.g., EEG and heart rate variability).

Methods

Dual N back training

The study will use a dual n-back task for WM training. In this task, squares at 8 different locations will show up sequentially (stimulus length, 500 ms; inter-stimulus interval, 2,500 ms) on a computer screen every 3 seconds. Simultaneously with the presentation of the squares, one of eight consonants will show up sequentially through a speaker. Participants will have to judge whether the location of a square and the consonant they heard matches the one n-back before (the same n value for both visual and auditory targets). Each training session has 20 blocks consisting of 20 + n trials and takes around 25 min. Each block includes six auditory and six visual targets (four appearing in only one modality, and two appearing in both modalities simultaneously) whose locations are random. Participants will have to make responses manually by pressing the mouse left-click button for visual targets and the right-click button for auditory targets. No responses were required for non-targets. If a target is correctly detected, a green flash will be given, which constitutes a positive feedback. If a target is falsely detected, a blue flash will be given, which constitutes a negative feedback. The dual N back training is designed to continuously vary its difficulty by modifying the WM load (i.e., the level of n) and thereby track the participants' performance. Each training session begins at n = 1. Participants' performance will be analyzed after each block and the level of n for the next block will be adapted according to the following principle. The level of n increases by 1 in the next block if the mistakes per modality made by the participant are<3. Conversely, n would decrease by 1 if the mistakes per modality made by the participant are>5. In all other cases, the n is kept unchanged. Participants will come to the laboratory and take part in the WM training sessions twice daily for 5 weekdays (total 10 sessions), with each session lasting for approximately 25 minutes. The time interval between twice-daily sessions will be >3 hours.

Online left-hemispheric frontoparietal theta (6Hz) in-phase tACS

θ tACS will be administered during the dual n-back task, starting at the beginning of each task and lasting for 20 min. In the active θ tACS condition, sinusoidal tACS will be delivered by two battery-operated devices connected with two 4 × 1 wire adaptors (Equalizer Box, NeuroConn, Ilmenau, Germany). The electrode montages used for θ tACS will be positioned at left frontoparietal locations. The stimulation electrodes of the 1st stimulator will be placed at the International 10-10 electrode position F1, F5, AF3, and FC3 (stimulation electrodes) and CPz (return electrode) to cover the left frontal cortex. For the 2nd stimulator, the stimulation electrodes will be placed at P1, P5, CP3, and PO3 (stimulation electrodes) and FCz (return electrode) to cover the left parietal cortex. A NeuroConn digital to analog converter (DAQ) will control the two stimulators and create an in-phase (synchronous) setup (0° relative phase difference between the output signals of the two tACS-stimulators).

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taipei, Taiwan, 114
        • Tri-Service General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 63 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Eligible participants aged 20-65 with DSM-V-defined schizophrenia or schizoaffective disorder.
  2. Duration of illness > 2 years.
  3. Being clinically stable and on an adequate therapeutic dose of antipsychotics for at least 8 weeks prior to enrolment.
  4. Agreement to participate in the study and provide the written informed consent.

Exclusion Criteria:

  1. Having unstable medical conditions, current psychiatric comorbidity or active substance use disorder (in exception to caffeine and/or tobacco).
  2. Having a history of seizures, meningitis or encephalitis.
  3. Having contraindications for transcranial electrical stimulation or transcranial magnetic stimulation, e.g., pacemakers, metallic or magnetic pieces in the head/brain, ear implants and other implantible brain medical devices.
  4. Having a history of intracranial neoplasms or surgery, or a history of severe head injuries or cerebrovascular diseases.
  5. Pregnancy or breastfeeding at enrollment.
  6. Skin lesions on scalp at the area of electrode application

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active theta (6Hz) in-phase tACS
θ tACS will be administered during the dual n-back task, starting at the beginning of each task and lasting for 20 min. In the active θ tACS condition, sinusoidal tACS will be delivered by two battery-operated devices (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) connected with two 4 × 1 wire adaptors (Equalizer Box, NeuroConn, Ilmenau, Germany), via 10 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), at 6 Hz frequency, 2 mA current intensity without DC offset, with 100 cycles ramp-up/ramp-down and a 0° relative phase, for 20 min, twice-daily on 5 consecutive weekdays.
See detail in arm/group descriptions regarding the intervention.
Sham Comparator: Sham tACS
During sham sessions, tACS will be applied in the synchronous condition for 30 s of 2 mA normal-like stimulation at the beginning of each dual n-back task. After that, only a tiny current pulse (110 μA over 15 ms) for impedance control took place every 550 ms during the remaining time.
See detail in arm/group descriptions regarding the intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The change over time in the negative symptoms subscale score of the Chinese version of the Positive and Negative Syndrome Scale (PANSS) (from baseline to the timepoints immediately after intervention, at one-week and one-month follow-ups).
Time Frame: Five weeks
A clinician-administered rating scale to measure the severity of psychopathological symptoms of the patients with schizophrenia spectrum disorder. The patient is rated from 1 to 7 on 30 different symptom items. All items scores are summed up to yield a total PANSS score, which ranges from 30 to 210. A higher score indicates greater psychopathological symptom severity. There are 7 items for positive symptoms subscale (score 7-49), 7 items for negative symptoms subscale (score 7-49), 16 items for general symptoms subscale (score 16-112).
Five weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The change over time in the Chinese version of the Positive and Negative Syndrome Scale Factor Score for Negative Symptoms (PANSS-FSNS) (from baseline to the timepoints immediately after intervention, at one-week and one-month follow-ups).
Time Frame: Five weeks
A clinician-administered rating scale to measure the severity of psychopathological symptoms of the patients with schizophrenia spectrum disorder. The patient is rated from 1 to 7 on 30 different symptom items. All items scores are summed up to yield a total PANSS score, which ranges from 30 to 210. A higher score indicates greater psychopathological symptom severity. The five-factor PANSS model can be obtained by calculating from 26 of 30 items of PANSS: positive (5 items, P1+P3+P5+P6+G9,score 5-35) , negative (7 items, N1+N2+N3+N4+N6+G7+G16, score 7-49), grandiosity/excitement (4 items, score 4-28), disorganization (5 items, score 5-35), and depression (4 items, score 4-28) factor scores. The cognitive component of the PANSS can be obtained as well (3 items, P2+N5+G11, score 3-21).
Five weeks
The change over time in the score of the Chinese version of the Scale for the Assessment of Negative Symptoms (SANS) (from baseline to the timepoints immediately after intervention, at one-week and one-month follow-ups).
Time Frame: Five weeks
The Scale for the Assessment of Negative Symptoms (SANS) is used to assess negative symptoms in schizophrenia on a 25 item, 6-point scale. The SANS measures five domains of the negative symptoms including affective flattening or blunting, alogia, avolition - apathy, anhedonia - Asociality, Attention. In each domain, separate symptoms are rated from 0 (absent) to 5 (severe). A total SANS score ranges from 0 to 125.
Five weeks
The change over time in the score of the Chinese version of the Personal and Social Performance scale (PSP) (from baseline to the timepoints immediately after intervention, at one-week and one-month follow-ups).
Time Frame: Five weeks
A clinician-administered rating scale to measure the psychosocial functioning of the patients with schizophrenia spectrum disorder. The PSP scale measures psychosocial functioning within four domains: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior.The patient is rated from 1 to 6 on each item of the four domains. A higher score indicates greater psychosocial functioning in any of the four domains. The final global score is defined according to a summary instruction table. This scale provides a single, overall rating from 1 to 100, where a higher score represents better personal and social function.
Five weeks
The change over time in the score of the self-reported version of the graphic personal and social performance scale (SRG-PSP) (from baseline to the timepoints immediately after intervention and at one-week follow-up)
Time Frame: Two weeks
The SRG-PSP is a self-rating scale of proven validity and reliability, comprising both male and female versions of cartoon-like pictures that are derived from the narrative text of the four domains of Personal and Social Performance (PSP) scale including the sub-items of socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behaviour.
Two weeks
The change over time in the score of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia (SUMD) (from baseline to the timepoints immediately after intervention, at one-week and one-month follow-ups).
Time Frame: Five weeks
An expert-rating scale based on a patient interview to measure patients' clinical insight. The abbreviated version of SUMD comprises 9 items measuring current states of awareness as follows: (1) a mental disorder, (2) consequences of a mental disorder, (3) effects of drugs, (4) hallucinatory experiences, (5) delusional ideas, (6) disorganized thoughts, (7) blunted affect, (8) anhedonia, and (9) lack of sociability. Scores on each item range from 0 to 3. A score of 0 indicates 'not applicable'; 1, 'aware'; 2, 'somewhat aware/unaware' and 3, 'severely unaware.' Based on the 3 dimensions approach of the abbreviated version of SUMD, the scores on the items 1-3, 4-6 and 7-9 were averaged to obtain the dimension score of 'awareness of the disease', 'awareness of positive symptoms', and 'awareness of negative symptoms', respectively. All dimension scores were linearized on a 0-100 scale, with 0 and 100 indicating the lowest and highest level of unawareness, respectively.
Five weeks
The change over time in the score of the Taiwanese version of the Beck Cognitive Insight Scale (BCIS) (from baseline to the timepoints immediately after intervention and at one-week follow-up)
Time Frame: Two weeks
Cognitive insight was measured by the Taiwanese version of the Beck Cognitive Insight Scale (BCIS), a self-reported instrument comprising 15 items.The Taiwanese BCIS is composed of 2 subscales including reflective attitude (9 items) and certain attitude (6 items). We obtained a R-C (reflective attitude minus certain attitude) index of the Taiwanese BCIS, representing the measurement of cognitive insight by subtracting the score of the certain attitude subscale from that of the reflective attitude subscale. Lower R-C index scores indicate poorer cognitive insight.
Two weeks
The change over time in the score of the Taiwanese version of the Self-Appraisal of Illness Questionnaire (SAIQ) (from baseline to the timepoints immediately after intervention and at one-week follow-up)
Time Frame: Two weeks
The Taiwanese version of the Self-Appraisal of Illness Questionnaire (SAIQ) was used to assess attitudes toward mental illness and experience of psychiatric treatment.This self-administered tool was composed of 17 items. The patients rated the extent to which they agreed with each statement of the item by using a four-point Likert scale, ranging from 1, ''do not agree at all'', to 4, ''completely agree''. Whether the scale score is in order from least to most or from the most to least depends on the content of the item statement. The total score of SAIQ ranges from 17 to 68.
Two weeks
The change over time in the negative symptoms subscale score of the Chinese version of the Schizophrenia Quality of Life Scale Revision Four (from baseline to the timepoints immediately after intervention and at one-week follow-up)
Time Frame: Two weeks
The Chinese version of the Schizophrenia Quality of Life Scale Revision Four is a self-administered questionnaire of 33 items in two domains: psychosocial and vitality. All but four items are coded on a scale of 0-4 according to the frequency of occurrence during the previous 7 days (0 = always, 4 = never; the four exceptions are coded 0 = never, 4 = always). A higher score indicates higher health-related QoL.
Two weeks
The changes over time in the results of Digit span (forward and backward) (from baseline to the timepoints immediately after intervention and at one-week follow-up)
Time Frame: Two weeks
A test to measure the capacity of working memory of the patients
Two weeks
The changes over time in the results of Finger tapping test (from baseline to the timepoints immediately after intervention and at one-week follow-up)
Time Frame: Two weeks
A neuropsychological test that examines motor functioning, specifically, motor speed and lateralized coordination.
Two weeks
The changes over time in the results of Continuous Performance (CPT, version 2.0) (from baseline to the timepoints immediately after intervention and at one-week follow-up)
Time Frame: Two weeks
A neuropsychological test that examines the performance of prefrontal-mediated task
Two weeks
The changes over time in the results of Wisconsin Card Sorting Test (WCST) (from baseline to the timepoints immediately after intervention and at one-week follow-up)
Time Frame: Two weeks
A neuropsychological test of "set-shifting", i.e. the ability to display flexibility in the face of changing schedules of reinforcement.
Two weeks
The changes over time in the results of Tower of London test (from baseline to the timepoints immediately after intervention and at one-week follow-up)
Time Frame: Two weeks
A neuropsychological test for the assessment of executive functioning specifically to detect deficits in planning, which may occur due to a variety of medical and neuropsychiatric conditions.
Two weeks
The changes over time in the results of Color Trails Test (CTT) (from baseline to the timepoints immediately after intervention and at one-week follow-up)
Time Frame: Two weeks
The CTT, a culture-neutral version of the Trail Making Test, was selected to measure sustained visual attention. The CTT consists of two parts (CTT-1 and CTT-2). The CTT-1 requires participants to connect a series of numbered circles that are randomly printed on a sheet of paper. In the CTT-2, numbered circles of 1 to 25 are shown twice (printed in pink and in yellow) randomly on a sheet of paper. Participants are asked to connect the numbers from 1 to 25 alternating between the two colors.
Two weeks
The changes over time in the results of Stroop Color Word Test (SCWT) (from baseline to the timepoints immediately after intervention and at one-week follow-up)
Time Frame: Two weeks
Stroop Color Word Test (SCWT), Chinese version; was administered to measure selective attention and cognitive flexibility. SCWT is composed of three parts, each lasting for 45 seconds.
Two weeks
The changes over time in the results of the dual 2-back task (from baseline to the timepoints immediately after intervention, at one-week and one-month follow-ups).
Time Frame: Five weeks
In the dual 2-back task, squares at 8 different locations will show up sequentially (stimulus length, 500 ms; inter-stimulus interval, 2,500 ms) on a computer screen every 3 seconds. Simultaneously with the presentation of the squares, one of eight consonants will show up sequentially through a speaker. Participants will have to judge whether the location of a square and the consonant they heard matches the one 2-back before (the same for both visual and auditory targets). Each experimental condition was presented with 100+n trials, resulting in a task time of 5 min. Each task includes 30 auditory and 30 visual targets (four appearing in only one modality, and two appearing in both modalities simultaneously) whose locations are random. Participants will have to make responses manually by pressing the mouse left-click button for visual targets and the right-click button for auditory targets. No responses were required for non-targets.
Five weeks
The changes over time in indices of heart rate variability (HRV) measured at baseline, during the first session of tACS, after 10-session tACS, at 1-week and 1-month follow-ups.
Time Frame: Five weeks
HRV indices represent autonomic functioning. ECG electrodes were placed on bilateral arms just below the elbows, with a ground electrode placed just above the right wrist bone. Lead I electrocardiogram of each patient was taken for 5 min after sitting and having a rest for 20 min in a soundproof, dim-lighted room with thermostatic control. At the four timepoints (baseline, after 10-session tACS, at 1-week and 1-month follow-ups), HRV will be collected during resting and during a dual 2-back task. The ECG signals were acquired, stored, pre-processed according to the recommended procedures and processed by an HRV analyser (LR8Z11, Yangyin Corp., Taipei, Taiwan). The time domain of HRV is obtained: Standard deviation of NN intervals (SDNN). Power spectrum of HRV is quantified into the standard frequency-domain measurements including low-frequency power (LF, 0.04-0.15 Hz), high-frequency power (HF, 0.15-0.40 Hz).
Five weeks
The changes over time in EEG absolute power and coherence in the frontoparietal electrode pairs in the alpha and theta range (from baseline to the timepoints after intervention, at one-week and one-month follow-ups)
Time Frame: Five weeks
In a recliner in a dimly lit, electrically shielded room, patients' EEGs were recorded at 4 timepoints (baseline, after 10-session tACS, at 1-week and 1-month follow-ups) by using the Neuro Prax® TMS/tDCS full-band DC-EEG system with 32 EEG Ag/AgCl electrodes in the standard 10-20 International placement. EEG will be collected during resting, eye-opened (5min) and during a dual 2-back task (5min). Signals will be amplified in the dynamic input range of ± 140 mV at a resolution of 0.5 μV by using EEG amplifiers and stored for offline analyses. Eye or muscle artifacts were automatically detected and removed using NeuroPrax's built-in software.
Five weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hsin-An Chang, M.D., Tri-Service General Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 14, 2019

Primary Completion (Actual)

April 10, 2020

Study Completion (Actual)

April 10, 2020

Study Registration Dates

First Submitted

September 3, 2020

First Submitted That Met QC Criteria

September 3, 2020

First Posted (Actual)

September 11, 2020

Study Record Updates

Last Update Posted (Actual)

September 23, 2020

Last Update Submitted That Met QC Criteria

September 20, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on Theta tACS

3
Subscribe